Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

Related Articles

FDA Accepts Ortho Dermatologic’s NDA for Novel Plaque Psoriasis Treatment, IDP-118

November 2, 2017

FDA Approves Jansen’s Golimumab for PsA, AS

October 24, 2017

FDA expands indications for SculpSure

October 19, 2017

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the plaque psoriasis drug guselkumab (Tremfya, Janssen-Cilag International NV) for approval.

The CHMP supported the use of guselkumab for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy, according to an EMA news release.

“We are pleased guselkumab may soon be available to adults living with moderate to severe plaque psoriasis in Europe, because the evidence shows this novel therapeutic offers significant and lasting efficacy for patients in need of alternative treatment options,” said José Antonio Burόn Vidal, Janssen vice president of medical affairs, Europe, Middle East, and Africa, in a statement.

The company said that 14 million people in Europe have plaque psoriasis.

Full Article